

INSTRUCTIONS

- Complete this reporting form for AEFIs listed in the BC Immunization Manual, Part 5 Section 6. Summary of Reporting Criteria in a vaccine recipient which follows immunization that cannot be clearly attributed to other causes. A causal relationship with the administration of the vaccine does not need to be proven.
- Public health staff: Enter into the public health information system used for AEFI in your region.
- <u>Community vaccine providers</u>: Submit the completed form to local public health. Complete all pertinent fields
 except for Section G & H. See the AEFI reporting map <u>here</u> for instructions on where to send the form according to
 health authority.
- For additional information on reporting criteria, clinical management and interpretation of AEFIs, as well as implications for subsequent immunization, please refer to <u>BC Immunization Manual, Part 5 – Adverse Events</u> <u>Following Immunization</u>.

Reporting Tips

Refer to the <u>User</u>
<u>Guide</u> for
Completion and
Submission of
AEFI Reports for
full instructions.

Following immunization.	
REPORTER INFORMATION	
Health Authority: FHA IHA NHA	VCH VIHA PHSA FNHA
Settin g: Physician office Public health Hospital Pl	harmacy Health authority workplace health
Other, specify:	
e.	Number: () _ ext Reporter is the health care provider who received and
Last First	reported the AEFI information to the
il: Fax Nui	mber () - public health unit.
Address:	Branch Office:
	(if applicable)
Province/Territory: Postal code:	Date reported:
	YYYY/MM/DD
Signature: MD RN	IMPACT Pharmacist Other, specify:
Reported to public health unit by: Reporter Client	Other, complete section A.
A. SOURCE OF INFORMATION	
Only complete Section A if "Other" selected for "Reported to publi	ic health unit by"
Name: Phone Nu	
Last First	Source of information can be
	the same as reporter, the client,
Address:	or a secondary source such as a parent/guardian.
Unit # Street #	Street Name City
	Province:
B. CLIENT INFORMATION	-Tovince.
Name:	
Last First	Middle
Date of Birth: Gender: Male	e Female Transgender Unknown
YYYY/MM/DD	



Health Card	Number:			Alternate Name	e(s):				Adverse event ID and PARIS ID are system generated
Phone Numb	OEF (home/work/mobile	e): ()		-	ext.				IDs, not reportable to local
Address:	Unit #	Street #	Stre	et Name			City		public health. Enter IMPACT Local Inventory Number if the
Postal Code:		Province:		Country of Reside	ence (if not Ca	nada):			report was received from IMPACT;
ADVERSE E	VENT ID:		IMPACT LIN	:	PARIS	S ID:			otherwise leave it blank.
PATIENT'S PH	IYSICIAN (OR PRIN	MARY CARE PROVIDE	ER)						
Name:			Phone Numb	per () -		Ext.		
Last	First	t							
Address:									
C. IMMUN	NIZATION DATA	4							
Date vaccine administere	Immunizing agent	Trade name	Manufacturer	Lot number	Dose #	Dosage/ unit	Route	Site	
YYYY/MM/DD									_
									_
									^Date of vaccine administered
									should be the same for all vaccines
									associated with a single AEFI
									report.
Health Care	Provider who adr	ministered the vacc	ine:	Phone:					
Address									
:	s## 04	2.	at Nama	2"					
	MATION AT TI		et Name ATION AND AEF	City	,				
			the above immuni		d in section	C?			
		_							
	t applicable (no p	rior doses)	Unknown	res (If yes , provide	e details bel	ow.)			
Comments:									
Did this AEF	I follow an inco	rrect immunizatio	n?						_
No Unkno	own Yes (If ves	choose all that an	oply and provide det	tails below):					
Given ou	tside the recomm	ended age limits	Product expired	d Dose excee	eded that red	commended	I for age		
Wrong va	accine given		Incorrect route	Other, spec	cify				



Comments:						
Medical history (up to time of AE	EFI onset)? Check all that ap	ply and provide deta	ails below.			
Concomitant medication(s)	Known medical conditions/	'allergies	Acute illne	ess/injury		
No known medical conditions(s)	Unknown at time of report					
Comments:						
E. AEFI DETAILS: Complete asterisk (*) should be diagno Section I for additional inform	osed by a physician. If not, p	provide sufficient info	eck all signs/sympto ormation to support	ms that apply. the selected it	Item(s) with em(s). Use	
E1. Local reaction at or near inj	jection site					
Onset: Min. <i>or</i> Hrs.	or Days from immun	nization to onset of 1	st symptom/sign			
Duratio Min. or Hrs.	or Days from 1st syn	nptom/sign to resolu	ition of all symptoms	s/signs	Unresolved	
Infected abscess* Sterile	abscess*	Cellulitis*	Nodule	Rash		Select applicable local reaction(s) before selecting symptoms/signs
Pain or redness or swelling exter	nds past the nearest joint	Adenopathy/Lymp	hadenitis*			on the following page.
Pain or redness or swelling persi	isting for 10 days or more	Other, specify:				For tips on where to report rash see Section L.
Local reaction section continues o	on the next page.					

E. AEFI DETAILS continued E1. Local reaction at or near injection site continued If an injection site reaction is reported above, check all symptoms/signs that apply and provide details below: Induration Swelling Pain Erythema Warmth Tenderness Largest diameter of vaccination site reaction (cm): Site(s) of reaction (e.g., LA, RA): Only select local signs/symptoms if one or more local reaction is Palpable fluctuance Fluid collection shown by imaging technique (e.g., MRI, CT, ultrasound) reported. Spontaneous/surgical Microbial results, specify Lymphangitic streaking Regional lymphadenopathy drainage Specify Microbial results in comment box. Comments:

Version Date: November 1, 2019 Page 3 of 9



E2. Anaphylaxis and other allergic events									
Onset: Mi	Min. or Hrs. or Days from immunization to onset of 1st symptom/sign								
Duratio n: Min. or Hrs. or Days from 1st symptom/sign to resolution of all symptoms/signs Unresolved									
Anaphylaxis	Oculo-Resp	iratory Syndrome	(ORS)	Other all	ergic events				
For the event ind	icated above, s	elect all symptom	s/signs th	at apply and pro	vide details ii	comments	below.		
Skin/ mucosal:	Generalized:	At injection	on site	Non-injection sit	е	Urticaria	Erythema		
_		Pruritus		Prickly sensation	1	Rash			
	Localized:	At injection	on site	Non-injection sit	е	Urticaria	Erythema		
		Pruritus		Prickly sensation	ı	Rash			Choose allergic signs/symptoms only if an allergic
	Eye(s):	Red bilate	eral	Red unilateral		Itchy			event (anaphylaxis, ORS, or Other
	Angioedema:	Tongue	Throat	Uvula	Larynx	Lip			allergic events) is being reported.
		Eyelids	Face	Limbs	Other,	specify:			If a client only reports GI
Cardiovascu lar:	Measured hyp	otension	↓ central p	oulse volume		Capillary re	fill time >3 se	ec	symptoms that are not allergic in nature, report in the appropriate
	Tachycardia		↓ or loss o	of consciousness					event in the "Other event" section.
Respiratory:	Sneezing	Rhinorrhea	Hoa	rse voice	Sensation o	f throat closu	ure	Stridor	For tips on where to report rash see Section L.
	Dry cough	Tachypnea	Whe	eezing	Increased us	se of access	ory muscles		see Section L.
	Grunting	Cyanosis	Sore	e throat	Indrawing/re	etractions			
	Difficulty swalle	owing	Che	st tightness	Difficulty bre	athing			
Gastrointestin al:	Diarrhea	Abdominal pain	Na	ausea V	omiting				
Laboratory:	Mast cell tryp	tase elevation > up	per norma	al limit					
Comments:									

E. AEFI DETAILS continued			
E3. Neuro	ologic event		
Onset:	Min. or Hrs. or	Days from immunization to onset of 1st symptom/sign	
Duration :	Min. or Hrs. or	Days from 1st symptom/sign to resolution of all symptoms/signs Unresolved	



Seizure(s) (Check all that apply):	
Febrile Afebrile Unknown type	
Focal or	
Generalized, specify: Tonic Clonic Tonic-clonic Atonic Myoclonic Absence	Item(s) with
Witnessed by health care professional: Yes No Unknown	asterisk (*) should be diagnosed by a physician.
Sudden loss of consciousness: Yes No Unknown	Select the appropriate
Previous history of seizures: Febrile Afebrile Unknown type	neurological event, before choosing corresponding descriptors.
Anaesthesia/ Paraesthesia* (Check all that apply):	Report "Myelitis/ Transverse
Generalized or Localized	myelitis, ADEM or SSPE" as "Other neurological diagnosis,
Numbness Tingling Burning Formication Other, specify:	specify". Report Vaccine-
Meningitis* Encephalopathy/Encephalitis* Guillain-Barre Syndrome (GBS)* Bell's Palsy*	associated Paralytic Poliomyelitis as "Other paralygia"
Other paralysis* Other neurological diagnosis*, specify:	"Other paralysis".
For any neurological event indicated above, check all that apply and provide details in comments below. Depressed/altered level of consciousness/Lethargy/ Personality change lasting ≥24 hrs Focal or multifocal neurologic sign(s) Fever (≥38°C) CSF abnormality EEG abnormality EMG abnormality Neuroimaging abnormality Brain/spinal cord histopathologic abnormality Comments:	
E4. Other defined events of interest	
Onset: Min. or Hrs. or Days from immunization to onset of 1st symptom/sign Duration Days from 1st symptom/sign to resolution of all symptoms/	
: Min. or Hrs. or Bays from 12- symptom/sign to resolution of all symptoms/ Unresolved	
Hypotonic-Hyporesponsive Episode* (age <2 years):	
Limpness Pallor/cyanosis Reduced responsiveness/unresponsiveness	
Persistent crying (continuous and unaltered crying for ≥3 hours)	
Rash: (Refer to Immunization Manual, Part 5 for reporting criteria. For rash at injection site or rash in allergic reaction, use sections above.)	
Generalized Localized at non-injection site	
Intussusception*	
Hematochezia*	
Arthritis*:	Item(s) with



Parotitis* (Parotid gland swelling with pain and/or tenderness)

Orchitis*

Thrombocytopenia*:

Platelet count <150×10⁹/L Petechial rash Other clinical evidence of bleeding

Fever ≥38°C (Report only if fever occurs in conjunction with reportable event. For a neurological event use section above.)

Syncope with injury

Severe vomiting

Severe diarrhea

Other serious or unexpected event(s) not listed above (Specify and provide details in comments below)

Comments:

F. IMPACT OF AEFI, OUTCOME, AND LEVEL OF CARE OBTAINED

Highest impact of AEFI (Choose one of the following): Outcome at time of report (Choose one of the following):

Did not interfere with daily activities Permanent disability/incapacity Fully recovered

Interfered but did not prevent daily activities Not yet recovered Unknown

Prevented daily activities Death; specify date:

YYYY/MM/DD

Highest level of care obtained (Choose one of the following):

Emergency visit Non-urgent visit Telephone advice from a health professional None Unknown

Admitted to Hospital (days) **OR** Resulted in prolongation of existing hospitalization (by days)

The state of the spiral form of the state of

Hospital name:

Yes, enter as an AEFI

Hospital admission date: Hospital discharge date:

YYYY/MM/DD YYYY/MM/DD

Treatment received: No Unknown Yes

Provide details of treatment, including self-treatment:

G. REPORTABILITY - FOR PUBLIC HEALTH USE ONLY

Does the event reported meet reporting criteria (See Section J)?

No, do not enter as an AEFI. If AEFI report was previously started in the public health

information system, set status to "Does not meet reporting criteria"

H. PUBLIC HEALTH RECOMMENDATIONS (Provide comments. Use section I if extra space is required.) FOR PUBLIC HEALTH USE ONLY

www.bccdc.ca

Version Date: November 1, 2019

For public health use only.

Report assessment in an emergency room setting without formal admission

to hospital as "Emergency Visit".

ioo omy.

Page 6 of 9



No chan	ge to immunization schedule	e Expert referral, specify			
Determine protective antibody level, specify		y Controlled	Controlled setting for next immunization, specify		
No furthe	er immunizations, <i>specify</i>	Active follo	ow up for AEFI recurrence after next vaccine, specify		
Other, sp	pecify	No recomi	mendations	For public health	
Commen	ts:		Provide name of MOH or designate making the recommendation.		
Name:		Professional status: MOH/	MHO MD RN Other, specify:		
Phone: () - Date Signature:			Signature:		
Send a co	opy to: BCCDC Client's Phy	ysician Other:			
Plea: Prov	PPLEMENTARY INFORMATION se indicate the section letter when ide details of any investigation or toted item(s). Append information of the section is the section of the section in the section in the section is the section in the section is the section in the section in the section in the section is the section in the section is the section in the section in the section in the section is the section in the section in the section in the section is the section in the section in the section in the section is the section in the sect	providing details. treatment for the recorded A	EFI. Provide sufficient information to support the		
Sectio n	Comments				
1 45	VERSE EVENTS FOLLOWIN	C IMMULNIZATION - BE	DODTARII ITV		
J. AD	VERSE EVENTS FOLLOWING	G IMMUNIZATION = RE	PURTABILITY		

Reportable: Any event listed in the BC Immunization Manual, Part 5 - Section 6. Summary of Reporting Criteria in a vaccine recipient which follows immunization that cannot be clearly attributed to other causes. A causal relationship with the administration of the vaccine does not need to be proven.

Does not meet reporting criteria: Any event which follows immunization that has been clearly attributed to other causes **OR** does not meet reporting criteria (e.g., not serious such as mild vomiting or diarrhea, temporal relationship incompatible with association with vaccine receipt).

K. ADVERSE EVENTS FOLLOWING IMMUNIZATION - TEMPORAL CRITERIA

The length of time between vaccine administration and onset of symptoms is an important consideration in causality assessment. Temporal criteria guidelines in this table are generally agreed upon approximate timelines.

Reaction	Advance French Fellowing Income institut	Temporal Criteria			
Type	Adverse Event Following Immunization	Inactivated Vaccines	Live Attenuated Vaccines		
	Infected Abscess	0-7 days			
Local	Sterile Abscess	0-7	days		
Reaction s at	Cellulitis	0-7 days			



injection Site	Nodule	0-7 days				
	Pain or Redness or Swelling		0-48 hours			
	Adenopathy/Lymphadenopathy	0-7 days	MMR: 5 - 30 days Varicella: 5 - 42 days			
	Fever	Timing in conjunction wi	ith other reportable adverse events			
Systemic Reaction	Hypotonic-Hyporesponsive Episode (HHE)	0-48 hours				
	Parotitis	Not applicable	MMR: 5-30 days			
S	Orchitis	Not applicable	MMR: 5-30 days			
	Rash	0-7 days	MMR: 0 - 30 days Varicella: 0 - 42 days			
	Screaming/Persistent crying		0-72 hours			
	Severe Vomiting/Diarrhea	0-72 hours	Rotavirus: 0-7 days			
Allergic	Anaphylaxis		0-24 hours			
Reaction	Oculo-respiratory Syndrome (ORS)	0-24 hours				
	Other Allergic Reactions		0-48 hours			
	Anaesthesia/Paraethesia	0-15 days	MMR: 0 - 30 days Varicella: 0 - 42 days			
	Bell's Palsy	0-3 months				
	Convulsion/Seizure	0-72 hours	MMR: 5 - 30 days Varicella: 5 - 42 days			
Neurolog ical	Encephalopathy or Encephalitis or Acute Disseminated Encephalomyelitis (ADEM)	0-42 days	MMR: 5 - 30 days Varicella: 5 - 42 days			
Events	Guillain-Barré syndrome (GBS)		0-8 weeks			
	Meningitis	0-15 days	MMR: 5 - 30 days Varicella: 5 - 42 days			
	Subacute sclerosing panencephalitis (SSPE)	Not applicable	Up to 10 years following a measles-containing vaccine			
	Paralysis	0-15 days	OPV: 5 - 30 days Varicella: 5-42 days			
Other	Arthritis	0-30 days	MMR: 5 - 30 days Varicella: 0 - 42 days			
	Intussusception or Haematochezia	Not applicable	Rotavirus: 0-42 days			
Events of	Syncope with injury	0	0-30 minutes			
Interest	Thrombocytopenia		0-30 days			
	Other severe or unusual	A temporal association to immunization and for which there is no oth known cause and not covered under the other categories				

L. RASH REPORTING TIPS

Version Date: November 1, 2019 Page 8 of 9



Localized rash at the injection site: Local reaction at or near injection site > Rash > Select details that apply > Specify any additional details in local comments.

Localized allergic rash: Anaphylaxis and other allergic events > Skin/mucosal > Localized > Select "At injection site" or "Non-injection site" > Select "Rash" > Specify details in allergic comments.

Generalized allergic rash: Anaphylaxis and other allergic events > Skin/mucosal > Generalized > Select "At injection site" and/or "Non-injection site" > Select "Rash" > Specify details in allergic comments.

Generalized rash: Other defined events of interest > Rash > Generalized > Specify details in other comments.

Localized rash at non-injection site: Other defined events of interest > Rash > Localized at non-injection site > Specify details in other comments.

NOTE: Additional relevant training materials and data standards are available on the Panorama Sharepoint (https://phsa.sp.gov.bc.ca/sites/PPHIS) (login required).

Version Date: November 1, 2019